CoChat

Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial

Raghu, Ganesh, Pellegrini, Carlos A, Yow, Eric, Flaherty, Kevin R, Meyer, Keith, Noth, Imre, Scholand, Mary Beth, Cello, John, Ho, Lawrence A, Pipavath, Sudhakar, Lee, Joyce S, Lin, Jules, Maloney, James, Martinez, Fernando J, Morrow, Ellen, Patti, Marco G, Rogers, Stan, Wolters, Paul J, Yates, Robert, Anstrom, Kevin J, Collard, Harold R · 2018 · The Lancet Respiratory Medicine
Cited by 144

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND Abnormal acid gastro-oesophageal reflux (GER) is hypothesised to play a role in progression of idiopathic pulmonary fibrosis (IPF). We aimed to determine whether treatment of abnormal acid GER with laparoscopic anti-reflux surgery reduces the rate of disease progression. METHODS The WRAP-IPF trial was a randomised controlled trial of laparoscopic anti-reflux surgery in patients with IPF and abnormal acid GER recruited from six academic centres in the USA. We enrolled patients with IPF, abnormal acid GER (DeMeester score of ≥14·7; measured by 24-h pH monitoring) and preserved forced vital capacity (FVC). We excluded patients with a FVC below 50% predicted, a FEV1/FVC ratio of less than 0·65, a history of acute respiratory illness in the past 12 weeks, a body-mass index greater than 35, and known severe pulmonary hypertension. Concomitant therapy with nintedanib and pirfenidone was allowed. The primary endpoint was change in FVC from randomisation to week 48, in the intention-to-treat population with mixed-effects models for repeated measures. This trial is registered with ClinicalTrials.gov, number NCT01982968. FINDINGS Between June 1, 2014, and Sept 30, 2016, we screened 72 patients and randomly assigned 58 patients to receive surgery (n=29) or no surgery (n=29). 27 patients in the surgery group and 20 patients in the no surgery group had an FVC measurement at 48 weeks (p=0·041). Intention-to-treat analysis adjusted for baseline anti-fibrotic use demonstrated the adjusted rate of change in FVC over 48 weeks was -0·05 L (95% CI -0·15 to 0·05) in the surgery group and -0·13 L (-0·23 to -0·02) in the non-surgery group (p=0·28). Acute exacerbation, respiratory-related hospitalisation, and death was less common in the surgery group without statistical significance. Dysphagia (eight [29%] of 28) and abdominal distention (four [14%] of 28) were the most common adverse events after surgery. There was one death in the surgery group and four deaths in the non-surgery group. INTERPRETATION Laparoscopic anti-reflux surgery in patients with IPF and abnormal acid GER is safe and well tolerated. A larger, well powered, randomised controlled study of anti-reflux surgery is needed in this population. FUNDING US National Institutes of Health National Heart, Lung and Blood Institute.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(18)30301-1

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 144

Metadata

Authors
Raghu, G., Pellegrini, C. A., Yow, E., Flaherty, K. R., Meyer, K., Noth, I., Scholand, M. B., Cello, J., Ho, L. A., Pipavath, S., Lee, J. S., Lin, J., Maloney, J., Martinez, F. J., Morrow, E., Patti, M. G., Rogers, S., Wolters, P. J., Yates, R., Anstrom, K. J., & Collard, H. R.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2018-09
Volume
6
Issue
9
Pages
707-714
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2887985837
Cited by
144
References
6
FWCI
13.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(18)30301-1
The paper
Raghu, G., Pellegrini, C. A., Yow, E., Flaherty, K. R., Meyer, K., Noth, I., Scholand, M. B., Cello, J., Ho, L. A., Pipavath, S., Lee, J. S., Lin, J., Maloney, J., Martinez, F. J., Morrow, E., Patti, M. G., Rogers, S., Wolters, P. J., Yates, R., . . . Collard, H. R. (2018). Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(18)30301-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.